Compare Cincinnati Financial Corporation (CINF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs TG Therapeutics Inc — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.58B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Cincinnati Financial Corporation is far larger — about 3.5× TG Therapeutics Inc's market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| CINF | TGTX | |
|---|---|---|
Market Cap | $26.58B | $7.64B |
Sector | Financials | Health |
52-Week High | $192.03 | $59.06 |
52-Week Low | $149.79 | $26.94 |
Enterprise Value | $25.71B | $7.84B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $172.55, down 0.75% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing revenue growth. Strong fundamentals include a low P/E of 8.18, robust ROE of 21.48%, and consistent dividend payments, with a recent H1-26 dividend of $0.94 declared.
Outlook remains cautiously optimistic with a consensus price target of $195, implying potential upside. Key risks include catastrophe losses impacting underwriting results and competitive pressures in commercial lines. The stock offers value based on earnings and dividend history but faces near-term headwinds from recent earnings miss and bearish technicals.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
